286 related articles for article (PubMed ID: 32276399)
41. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
42. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients.
Naz Z; Wahid B; Usman S; Saleem K; Rafique S; Ali A; Idrees M
J Interferon Cytokine Res; 2018 Jun; 38(6):255-260. PubMed ID: 29920131
[TBL] [Abstract][Full Text] [Related]
43. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT; Makowska Z; Duong FHT; Merkofer F; Filipowicz M; Baumert TF; Tornillo L; Terracciano L; Heim MH
Gastroenterology; 2012 Sep; 143(3):777-786.e6. PubMed ID: 22677194
[TBL] [Abstract][Full Text] [Related]
44. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Zhu H; Butera M; Nelson DR; Liu C
Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
[TBL] [Abstract][Full Text] [Related]
45. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
46. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
Matsuura K; Watanabe T; Tanaka Y
J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
[TBL] [Abstract][Full Text] [Related]
47. [Interferon].
Tamori A; Kawada N
Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis E virus persists in the presence of a type III interferon response.
Yin X; Li X; Ambardekar C; Hu Z; Lhomme S; Feng Z
PLoS Pathog; 2017 May; 13(5):e1006417. PubMed ID: 28558073
[TBL] [Abstract][Full Text] [Related]
49. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
50. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness.
Sung PS; Cheon H; Cho CH; Hong SH; Park DY; Seo HI; Park SH; Yoon SK; Stark GR; Shin EC
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10443-8. PubMed ID: 26216956
[TBL] [Abstract][Full Text] [Related]
51. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
52. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis C virus and intracellular antiviral response.
Lee J; Ou JJ
Curr Opin Virol; 2022 Feb; 52():244-249. PubMed ID: 34973476
[TBL] [Abstract][Full Text] [Related]
54. Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells.
Grabski E; Wappler I; Pfaender S; Steinmann E; Haid S; Dzionek A; Pietschmann T; Kalinke U
J Virol; 2015 Mar; 89(6):3200-8. PubMed ID: 25552725
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
56. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Feld JJ; Hoofnagle JH
Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
[TBL] [Abstract][Full Text] [Related]
57. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
Vachon ML; Dieterich DT
Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
[TBL] [Abstract][Full Text] [Related]
58. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
[TBL] [Abstract][Full Text] [Related]
59. Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
Ferrari SM; Fallahi P; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Colaci M; Giuggioli D; Ferri C; Antonelli A
J Immunol Res; 2019; 2019():5878960. PubMed ID: 31485460
[TBL] [Abstract][Full Text] [Related]
60. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
Thompson A; Patel K; Tillman H; McHutchison JG
J Hepatol; 2009 Jan; 50(1):184-94. PubMed ID: 19022518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
